Company intelligence / Profile preview

北京银谷医药科技

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Yingu Pharmaceutical Technology Co., Ltd. is a Chinese biotechnology and pharmaceutical company based in Beijing. It is an affiliate of Yingu Holding Group and focuses on the research and development of innovative chemical drugs. The company's lead clinical program is SY-606 (phencynonate bromide eye drops), a highly selective muscarinic acetylcholine receptor antagonist currently in Phase 1 clinical development for delaying the progression of myopia in children. Beijing Yingu Pharmaceutical Technology operates independently from its former affiliate, Yingu Pharmaceutical Co., Ltd., which was acquired by Henan Lingrui Pharmaceutical in early 2025.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 北京银谷医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 北京银谷医药科技.

Explore the full profile